An innovative clinical study has found that delivering regenerative cells to developing infants affected by spina bifida while undergoing fetal surgery could constitute a "important advancement" in addressing congenital conditions.
Study Parameters and Security
The American study examined six developing infants with the 'open' form of spina bifida. Surgeons applied placenta-derived mesenchymal stem cells directly onto the developing neural column during the repair procedure.
Importantly, the stem cell application was found to be safe. Researchers confirmed that the therapy did not induce cancerous growths, hinder surgical recovery, or prevent the reversal of co-occurring hindbrain herniation.
Positive Developments
Post-birth MRI scans indicated a complete reversal of hindbrain herniation in each of the babies. This neurological improvement is strongly associated with enhanced physical outcomes.
"Should it enable more children able to walk who otherwise would not, it could establish itself as their standard of care," noted the study director. "The outcomes appear profoundly encouraging and create a pathway toward lots of potential novel therapies."
Long-Term Prospects and Optimism
Independent medical specialists have suggested that subsequent studies of these apparent benefits could signal a "different age" in fetal surgery. The prospect of enhancing neural deficits occurring during fetal development is viewed as a revolutionary objective.
Notably important would be better management of bladder and bowel function, which are common challenges for individuals living with this condition.
Looking Ahead
Despite this being a first-in-human effort was small in scale, its established security and encouraging indicators create a solid basis for broader investigative efforts. The combination of regenerative medicine with established fetal surgery techniques offers substantial hope for improving the prognosis for infants diagnosed prenatally with spina bifida.